PCI The Journeys Within

Current Edition

Frankfurt 2027 – 12/10/26
ramusmedical
Regional News

Merck’s reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-onco...
Continue Reading →
Regional News

Amgen’s Repatha gains an edge on rival Praluent with FDA approval to treat children with rare cholesterol condition

Though it has struggled to live up to early commercial expectations, Amgen’s cholesterol treatment Repatha has largely had the best of its rival in the market, Sanofi...
Continue Reading →
Regional News

Hikma bolsters injectables franchise with $425M deal for Custopharm, but FTC review looms

Generics giant Hikma is boosting its injectables business to nearly 130 products in the U.S. by way of dealmaking. For $375 million upfront and another $50 million i...
Continue Reading →
Regional News

GlaxoSmithKline’s long-acting HIV drug nabs FDA priority review as a preventative option

GlaxoSmithKline’s long-acting HIV drug cabotegravir is already challenging market leaders as part of an approved treatment regimen. Now, the medicine is a step closer...
Continue Reading →
Regional News

Amid new pricing pressure, Lilly cuts cost of generic insulin by another 40%

With drugmakers facing renewed calls to lower the cost of prescription drugs, Eli Lilly has taken preemptive action, dropping the cost of its generic insulin by 40%. ...
Continue Reading →
Regional News

FDA’s Marks takes over vaccines office as agency prepares to part ways with 2 key officials

Amid the heated debate over COVID-19 booster shots, two key FDA vaccine experts said they'd be leaving the agency last month. In an effort to smooth over the transiti...
Continue Reading →
Regional News

Emmes Standardises on Veeva Development Cloud to Streamline Product Development

Global CRO builds technology foundation to drive scalability, efficiency, and compliance PLEASANTON, CA — Sept. 16, 2021 — Veeva Systems (NYSE: VEEV) today announced ...
Continue Reading →
Regional News

In newly diagnosed stomach cancer, 2 Opdivo-Yervoy flops show immunotherapy alone might not be the answer

Bristol Myers Squibb boasts a historic go-ahead for Opdivo plus chemotherapy as the first immunotherapy regimen for previously untreated stomach cancer. But the PD-1 ...
Continue Reading →
Regional News

Novartis, determined to dethrone Pfizer, will launch bold Kisqali-Ibrance head-to-head trial in breast cancer

Despite two life extension wins, Novartis still finds it tough to convince doctors to use its breast cancer drug Kisqali over Pfizer’s first-to-market Ibrance. Now, w...
Continue Reading →
Regional News

ESMO: Bristol Myers’ Opdivo-Yervoy, Pfizer-Merck KGaA’s Bavencio hit walls in head and neck cancer

Suffering two separate clinical trial blows, Bristol Myers Squibb and a collaboration between Merck KGaA and Pfizer learned the hard way that head and neck cancer is ...
Continue Reading →
Quotient